Endothelin receptor antagonists in cardiology clinical trials

Bibliography

• YANAGISAWA M, KURIHARA H, KIMURA S et al.: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature (1988) 332:411–415.
   PubMed Web of Science ®Google Scholar
• ••First study describing endothelin.
   Google Scholar
• IKEGAWA R, MATSUMURA Y, TSUKAHARA Y, TAKAOKA M, MORIMOTO S: Phosphoramidon, a metalloproteinase inhibitor, suppresses the secretion of endothelin 1 from cultured endothelial cells by inhibiting a big endothelin-1 converting enzyme. Biochem. Biophys. Res. Commun. (1990) 171:669–675.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI M, MATSUSHITA Y, LIJIMA Y, TANZAWA K: Purification and characterization of endothelin-converting enzyme from rat lung. Biol. Chem. (1993) 268:21394–21398.
   Web of Science ®Google Scholar
• OHNAKA K, TAKAYANAGI R, NISHIKAWA M, HAJI M, NAWATA H: Purification and characterization of endothelin-converting enzyme from rat lung. Biol. Chem. (1993) 268:26759–26766.
   Web of Science ®Google Scholar
• SHIMADA K, TAKAHASHI M, TANZAWA K: Cloning and functional expression of endothelin-converting enzyme from rat endothelial cells. Biol. Chem. (1994) 269:18275–18278.
   Web of Science ®Google Scholar
• HAYNES WG, STRACHAN FE, WEBB DJ: Endothelin ET(A) and ET(B) receptors cause vasoconstriction of human resistance and capacitance vessels in vivo. Circulation (1995) 92:357–363.
   PubMed Web of Science ®Google Scholar
• WENZEL RR, DUTHIERS N, NOLL G, BUCHER J, KAUFMANN U, LOSCHER TF: Endothelin and calcium antagonists in the skin microcirculation of patients with coronary artery disease. Circulation (1991) 94:316–322.
   Google Scholar
• VERHAAR MC, STRACHAN FE, NEWBY DE et al.: Endothelin-A receptor antagonist-mediated vasodilation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation (1998) 97:752–756.
   PubMed Web of Science ®Google Scholar
• •Interesting findings.
   Google Scholar
• BOULANGER G, LOSCHER TF: Release of endothelin from the porcine aorta: inhibition by endothelium-derived nitric oxide.' Clin. Invest. (1990) 85:587–590.
   Google Scholar
• •Important findings.
   Google Scholar
• LERMAN A, SANDOK EK, HILDEBRAND FL JR, BURNETT JC JR: Inhibition of endothelium-derived relaxing factor enhances endothelin-mediated vasoconstriction. Circulation (1992) 85:1894–1898.
   PubMed Web of Science ®Google Scholar
• •Important findings.
   Google Scholar
• PEIFLEY KA, WINKLES JA: Angiotensin II and endothelin-1 increase fibroblast growth factor-2 mRNA expression in vascular smooth muscle cells. Biochem. Biophys. Res. Commun. (1998) 242:202–208.
   PubMed Web of Science ®Google Scholar
• WOODCOCK EA, TANNER JK, CAROCCIA LM, LITTLE PJ: Mechanisms involved in the stimulation of aldosterone production by angiotensin II, vasopressin and endothelin. Clin. Exp. Pharmacol. Physiol. (1990) 17:263–267.
   PubMed Web of Science ®Google Scholar
• MOREAU P, D'USCIO LV, SHAW S, TAKASE H, BARTON M, LOSCHER TF: Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET (A)-receptor antagonist. Circulation (1997) 96:1593–1597.
   PubMed Web of Science ®Google Scholar
• CUNNINGHAM ME, HURIBAL M, BALA RJ, MCMILLEN MA: Endothelin-1 and endothelin-4 stimulate monocyte production of cytokines. Crit. Care Med. (1997) 25:958–964.
   PubMed Web of Science ®Google Scholar
• KOJIMA T, HATTORI K, HIRATA Y et al: Endothelin-1 has a priming effect on production of superoxide anion by alveolar macrophages: its possible correlation with bronchopulmonary dysplasia. Pediatr. Res. (1996) 39:112–116.
   PubMed Web of Science ®Google Scholar
• IWASAKI S, HOMMA T, MATSUDA Y, KON: Endothelin receptor B subtype B mediates autoinduction of endothelin-1 in rat mesangial cells. Biol. Chem. (1995) 270:6997–7003.
   Web of Science ®Google Scholar
• DUPUIS J, STEWART DJ, CERNACEK P, GOSSELIN G: Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation (1996) 94:1578–1584.
   PubMed Web of Science ®Google Scholar
• •Important findings.
   Google Scholar
• KIOWSKI W, SOTSCH G, HUNZIKER P et al: Evidence for endothelin-l-mediated vasoconstriction in severe chronic heart failure. Lancet (1995) 346:732–736.
   PubMed Web of Science ®Google Scholar
• •Important findings.
   Google Scholar
• MCMURRAY JJ, RAY SG, ABDULLAH I,DARGIE HJ, MORTON JJ: Plasma endothelin in chronic heart failure. Circulation (1992) 85:1374–1379.
   PubMed Web of Science ®Google Scholar
• WEI CM, LERMAN A, RODEHEFFER RJ et al: Endothelin in human congestive heart failure. Circulation (1994) 89:1580–1586.
   PubMed Web of Science ®Google Scholar
• PACHER R, STANEK B, HOLSMANN M et al.: Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. Am. Coll Cardiol. (1996) 27:633–641.
   PubMed Web of Science ®Google Scholar
• •Prognostic value of endothelin in heart failure.
   Google Scholar
• POUSSET F, ISNARD R, LECHAT P et at.: Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur. Heart J. (1997) 18:254–258.
   Google Scholar
• HOLSMANN M, STANEK B, FREY Bet al.: Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure. Am. Coll Cardiol. (1998) 32:1695–1700.
   Google Scholar
• •Interesting findings.
   Google Scholar
• CODY RJ, HAAS GJ, BINKLEY PF, CAPERS Q, KELLEY R.: Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation (1992) 85:504–509.
   Google Scholar
• •Interesting findings.
   Google Scholar
• LERMAN A, KUBO SH, TSCHUMPERLIN LK, BURNETT JC JR: Plasma endothelin concentrations in humans with end stage heart failure and after heart transplantation. Am. Coll Cardiol (1992) 20:849–853.
   PubMed Web of Science ®Google Scholar
• KRUM H, GOLDSMITH R, WILSHIRE-CLEMENT M, MILLER M, PACKER M: Role of endothelin in the exercise intolerance of chronic heart failure. Am. I Cardiol. (1995) 75:1282–1283.
   PubMed Web of Science ®Google Scholar
• Optimism returns to heart failure R&D: SCRIP World Pharmaceutical News (1995) 2014:27–28.
   Google Scholar
• SOTSCH G, KIOWSKI W, YAN X-W et al: Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation (1998) 98:2262–2268.
   PubMed Web of Science ®Google Scholar
• •ET antagonism and haemodynarnics in patients with heart failure.
   Google Scholar
• PACKER M, CASPI A, CHARLON V et al: Multicenter, double-blind, placebo-controlled study of long-term endothelin blockade with bosentan in chronic heart failure-results of the REACH-1 trial. Circulation (1998) 98 (Suppl. S):12.
   Google Scholar
• ACTELION LTD: Actelion shows accelerated growth for second quarter. Press
   Google Scholar
• ••
   Google Scholar
• ••
   Google Scholar
• ••54.Release (2000) August 8.
   Google Scholar
• TORRE-AMIONE G, YOUNG JB, DURAND JB et al: Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure. Circulation (2001)103:973–980.
   PubMed Web of Science ®Google Scholar
• TORRE-AMIONE G: RITZ (Randomized Intravenous TeZosentan) II. American College of Cardiology (2001).
   Google Scholar
• ••ET antagonism in acute heart failure.
   Google Scholar
• TEERLINK JR: RITZ (Randomized Intravenous TeZosentan) I. European Socieg, of Cardiology(2001).
   Google Scholar
• ••Currently largest trial examining ETantagonism in heart failure.
   Google Scholar
• O'CONNOR CM: RITZ (Randomized Intravenous TeZosentan) IV American Heart Association (2001).
   Google Scholar
• GENENTECH INC: Genentech, Inc. announces that Phase III trial of intravenous endothelin receptor antagonist tezosentan for acute heart failure shows positive hemodynamic results. Press Release (2001) February 13
   Google Scholar
• Banyu's new drugs R&D pipeline Pharma Japan (1999) 1676 (December 13) 21–37.
   Google Scholar
• SPIEKER LE, MITROVIC V, NOLL G et al.: Acute hemodynamic and neurohumoral effects of selective ETA-receptor blockade in patients with congestive heart failure. J. Am. Coll. Cardiol. (2000) 35:1745–1752.
   PubMed Web of Science ®Google Scholar
• RUSCHITZKA FT, PACHER R, KRANKENHAUS A et al: Chronic selective ETA receptor blockade in congestive heart failure: The HEAT trial (Heart failure ETA receptor blockade trial). Circulation (2000) 102(18): Abs 2876.
   Google Scholar
• ••Effects of chronic ET-A receptor blockade incongestive heart failure.
   Google Scholar
• BERGLER KLEIN J, PACHER R, BERGER R, BOJIC A, STANEK B: Neurohumoral and hemodynamic effects of the selective endothelin antagonist LU 135252 in advanced heart failure. Circulation (2000) 102(18): Abs 816.
   Google Scholar
• RUSCHITZKA F, ENSELEIT F, HURLIMANN D, NOLL G, LOSCHER TF: Selective ETA blockade improves hemodynamics without neurohumoral activation or impairment of renal function in congestive heart failure. Circulation (2001) 104:11-199, Abs 954.
   Google Scholar
• BERGER R, STANEK B, HUELSMANN M et al.: Effects of endothelin A receptor blockade on endothelial function in patients with chronic heart failure. Circulation (2001) 103:981–986.
   PubMed Web of Science ®Google Scholar
• •Interesting findings.
   Google Scholar
• SMITH W, BRUCE I, LEJEMTEL T et al.: Improved hemodynamics with the ETA selective receptor antagonist BMS-193884 in patients with heart failure. J Am. Coll. Cardiol. (2000) 34:241A, Abs 909–6.
   Google Scholar
• MURUGESAN N: Discovery of BMS-193884, a potent and selective ETA receptor antagonist ACS meeting (2000) 219th (San Francisco) MEDI 164.
   Google Scholar
• 001 H, COLUCCI WS, GAUTHIER DF, KEANE LM, ZACHARIAH BJ, GIVERTZ MM: Endothelin mediates local pulmonary vascular tone in patients with heart failure: demonstration by direct intrapulmonary infusion of sitaxsentan. Circulation (2001) 104: 11–497, Abs 2354.
   Google Scholar
• TEXAS BIOTECHNOLOGY CORP: Texas Biotechnology reports positive Phase IIa trial results of endothelin receptor antagonist in CHF Press Release (1998) February 11.
   Google Scholar
• TEXAS BIOTECHNOLOGY CORP: Texas Biotechnology reports additional positive Phase IIA trial results in congestive heart failure Press Release (1998) July 21.
   Google Scholar
• GLAXOSMITHKLINE PLC: Product development pipeline: February 2001 Company Brochure (2001) .
   Google Scholar
• Cardiovascular Therapeutic Review: Roche Hoare Covett-Pharmaceuticals Sector Research (1997) May.
   Google Scholar
• BioPartnering - Tanabe Seiyaku Annual Biopartnering Europe Meeting 8th (2000) October 16–17.
   Google Scholar
• BURRELL KM, MOLENAAR P, DAWSON PJ, KAUMANN AJ: Contractile and arrhythmic effects of endothelin receptor antagonists in human heart M vitro: blockade with SB 209670. J Pharmacol. Exp. Ther. (2000) 292:449–459.
   PubMed Web of Science ®Google Scholar
• BRUNNER F, KUKOVETZ WR: Postischemic antiarrhythmic effects of angiotensin-converting enzyme inhibitors. Role of suppression of endogenous endothelin secretion. Circulation (1996) 94:1752–1761.
   Google Scholar
• WINKLES JA, ALBERTS GF,BROGI E, LIBBY P: Endothelin-1 and endothelin receptor mRNA expression in normal and atherosclerotic human arteries. Biochem. Biophys. Res. Commun. (1993) 191:1081–1088.
   PubMed Web of Science ®Google Scholar
• LERMAN A, EDWARDS BS, HALLETT JW, HEUBLEIN DM, SANDBERG SM, BURNETT JC JR: Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. New Engl. J. Med. (1991) 325:997–1001.
   PubMed Web of Science ®Google Scholar
• •Important findings. LERMAN A, HOLMES DR JR, BELL MR, GARRATT KN, NISHIMURA RA, BURNETT JC JR: Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation (1995) 92:2426-2431. Important findings.
   Google Scholar
• KOHNO M, YOKOKAWA K, YASUNARI K, KANO H, MINAMI M, YOSHIKAWA J: Effect of the endothelin family of peptides on human coronary artery smooth-muscle cell migration. J Cardiovasc. Pharmacol. (1998) 31:S84–S89.
   PubMed Web of Science ®Google Scholar
• BEST PJM, LERMAN A: Endothelin in cardiovascular disease: from atherosclerosis to heart failure. ./. Cardiovasc. Pharmacol (2000) 35 (Suppl. 2.):561–563.
   Google Scholar
• RAY SG, MCMURRAY JJ, MORTON JJ, DARGIE HJ: Circulating endothelin in acute ischemic syndromes. Br. Hearff. (1992) 67:383–386.
   PubMed Web of Science ®Google Scholar
• MIYAUCHI T, YANAGISAWA M, TOMIZAWA T et al.: Increased plasma concentrations of endothelin-1 and big endothelin-1 in acute myocardial infarction (letter). Lancet (1989) 2:53–54.
   PubMed Web of Science ®Google Scholar
• OMLAND T, TERJE LIE R, AAKVAAG A, AARSLAND T, DICKSTEIN K: Plasma endothelin determination as a prognostic indicator of one year mortality after acute myocardial infarction. Circulation (1994) 89:1573–1579.
   PubMed Web of Science ®Google Scholar
• •Prognostic value of ET in acute myocardial infarction. WENZEL RR, FLEISH M, SHAW S et al: Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease. Circulation (1998) 98(21): 2235–2240. Important findings. KINLAY S, BEHRENDT D, WAINSTEIN M et al:Role of Endothelin-1 in the active constriction of human atherosclerotic coronary arteries. Circulation (2001) 104:1114-1118. Interesting findings.
   Google Scholar
• KNOLL AG: Knoll and Hoechst Marion Roussel announce alliance to codevelop compound for chronic heart failure and high blood pressure Press Release (1998) December 22.
   Google Scholar
• ABBOT LABORATORIES: Drug development pipeline-Abbott Laboratories. From a presentation by Miles D White CEO of Abbott at the Merrill Lynch Global Healthcare Conference. February 6–8, 2001. Company World Wide Web site (2001).
   Google Scholar
• CANNAN CR, BURNETT JR JC, BRANDT RR, LERMAN A: Endothelin at pathophysiological concentrations mediates coronary vasoconstriction via the endothelin-A receptor. Circulation (1995) 92:3312–3317Important findings.
   PubMed Web of Science ®Google Scholar
• WATANABE T, AWANE Y, IKEDA S et al.: Pharmacology of a non-selective ET(A) and ET(B) receptor antagonist, TAK-044 and the inhibition of myocardial infarct size in rats. Br: J. Pharmacol (1995) 114:949–954.
   Google Scholar
• KOJIMA M, KUBO K, FUJI WARA S, KANDORI H, CHATANI F, WATANABE T: Effects of TAK-044, an endothelin receptor antagonist, in a canine model of ischemia-reperfusion induced myocardial infarction. Japan. Pharmacol (1995) 67:266P–
   Google Scholar
• GROVER GJ, DZWONCZYK S, PARHAM CS: The endothelin-1 receptor antagonist BQ-123 reduces infarct size in a canine model of coronary occlusion and reperfusion. Cardiovasc. Res (1993) 27:1613–1618.
   PubMed Web of Science ®Google Scholar
• CANNAN CR, BURNETT JR JC, LERMAN A: Enhanced coronary vasoconstriction to endothelin-B receptor activation in experimental congestive heart failure. Circulation (1996) 93:646–651.
   PubMed Web of Science ®Google Scholar
• DOUGLAS SA, VICKERYCLARK LM, LOUDEN C, ELLIOTT JD, OHLSTEIN EH: Endothelin receptor subtypes in the pathogenesis of angioplasty-induced neointima formation in the rat: a comparison of selective ET(A) receptor antagonism and dual ET(A/B) receptor antagonism using BQ-1223 and SB 209670. Cardiovascular Pharmacol (1995) 26\(Suppl. 3): S186–S189.
   Google Scholar
• DOUGLAS SA, VICKERYCLARK LM, LOUDEN C, OHLSTEIN EH: Selective ET(A) receptor antagonism with BQ-123 is insufficient to inhibit angioplasty induced neointima formation in the rat. Cardiovascular Research (1995) 29(5):641–646.
   PubMed Web of Science ®Google Scholar
• MCKENNA CJ, BURKE SE, OPGENORTH TJ et al.: Selective ET(A) receptor antagonism reduces neointimal hyperplasia in a porcine coronary stent model. Circulation (1998) 97:2551–2556.
   PubMed Web of Science ®Google Scholar
• •Important findings.
   Google Scholar
• KOWALA MC, ROSE PM, STEIN PD et al.: Selective blockade of the endothelin subtype A receptor decreases early atherosclerosis in hamsters fed cholesterol. Pathol (1995) 146:819–826.
   Web of Science ®Google Scholar
• DAY R, LARIVIERE R, SCHIFFRIN EL: in situ hybridization shows increased endothelin-1 mRNA levels in endothelial cells of blood vessels of deoxycorticosterone acetate-salt hypertensive rats. Jim. I Hypertens. (1995) 8:294–300.
   PubMed Web of Science ®Google Scholar
• LI JS, SCHURCH W, SCHIFFRIN EL: Renal and vascular effects of chronic endothelin receptor antagonism in malignant hypertensive rats. Jim. .1 Hypertens. (1996) 9:803–811.
   PubMed Web of Science ®Google Scholar
• D USCIO LV, BARTON M, SHAW S, MOREAU P, LOSCHER TF: Structure and function of small arteries in salt-induced hypertension-effects of chronic endothelin-subtype-A-receptor blockade. Hypertension (1997) 30:905–911.
   PubMed Web of Science ®Google Scholar
• LARIVIERE R, THIBAULT G, SCHIFFRIN EL: Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive but not in spontaneously hypertensive rats. Hypertension (1993) 21:294–300.
   PubMed Web of Science ®Google Scholar
• KURIHARA Y, KURIHARA H, SUZUKI H et al.: Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature (1994) 368:703–710.
   PubMed Web of Science ®Google Scholar
• ITO H, ADACHI S, TAMAMORI M et al:Mild hypoxia induces hypertrophy of cultured neonatal rat cardiomyocytes: a possible endogenous endothelin-1 mediated mechanism. Ma Cell Cardiol (1996) 28:1271–1277.
   PubMed Web of Science ®Google Scholar
• KADDOURA S, FIRTH JD, BOHELER KR, SUGDEN PH, POOLE-WILSON PA: Endothelin-1 is involved in norepinephrine-induced ventricular hypertrophy in vivo acute effects of bosentan, an orally active, mixed endothelin ET-A and ET-B receptor antagonist. Circulation (1996) 93:2068–2079.
   PubMed Web of Science ®Google Scholar
• KRUM H, VISKOPER RJ, LACOURCIERE Y, BUDDE M, CHARLON V: The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. New Engl. Med. (1998) 338(12):784–790.
   PubMed Web of Science ®Google Scholar
• ••ET-A/B receptor antagonism in patientswith arterial hypertension.
   Google Scholar
• TADDEI S, VIRDIS A, GHIADONI L, SUDANO I, NOTARI M, SALVETTI A: Vasoconstriction to endogenous endothelin-1 is increased in the peripheral circulation of patients with essential hypertension. Circulation (1999) 100 (16):1680–1683.
   PubMed Web of Science ®Google Scholar
• •Interesting findings.
   Google Scholar
• NAKOV R, PFARR E, EBERLE S (on behalf of the HEAT-2 investigators): HEAT-2 (Hypertension: Endothelin Antagonist Treatment) presented during the European Society of Cardiology meeting (2001).
   Google Scholar
• ••ET-A receptor antagonism in patients witharterial hypertension.
   Google Scholar
• TEXAS BIOTECHNOLOGY CORP: Texas Biotechnology reports progress on Endothelin A receptor antagonist program Press Release (1999) October 14.
   Google Scholar
• SOCIETY FOR MEDICINES RESEARCH SYMPOSIUM: Endothelins; new therapeutic opportunities. Iddb Meeting Report (1996) December 12.
   Google Scholar
• PFIZER INC: Wallstreet analysts meeting Company Communication (2000) December 11.
   Google Scholar
• VERHAAR MC, STRACHAN FE, NEWBY DE et al.: Endothelin-A receptor antagonist-mediated vasodilation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation (1998) 97:752–756.
   PubMed Web of Science ®Google Scholar
• BARTON M, D -USCIO LV, SHAW S, MEYER P, MOREAU P, LOSCHER TF: ET(A) receptor blockade prevents increased tissue endothelin-1 vascular hypertrophy and endothelial dysfunction in salt-sensitive hypertension. Hypertension (1998) 31:499–504.
   PubMed Web of Science ®Google Scholar
• YANG Z, KRASNICI N, LOSCHER TF: Endothelin-1 potentiates smooth muscle cell growth to PDGF: role of ETA and ETB receptor blockade. Circulation (1999) 100:5–8
   PubMed Web of Science ®Google Scholar
• 0-LEAVY DH, POLAK JF, KRONMAL RA, MANOLIO TA, BURKE GL, WOLFSON SK JR: Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults: Cardiovascular Health Study Collaborative Research group. N Engl. .1. Med. (1999) 340:14–22.
   Google Scholar
• RUBIN LJ: Primary pulmonary hypertension. N Engl. J. Med. (1997) 336:111–117.
   PubMed Web of Science ®Google Scholar
• •Excellent review.
   Google Scholar
• GIAID A, SALEH D: Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl. J. Med. (1995) 333:214–221.
   PubMed Web of Science ®Google Scholar
• •Important findings.
   Google Scholar
• GIAID A, YANAGISAWA M, • LANGLEBEN D et al.: Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N EngL I Med. (1993) 328:1732–1729.
   Google Scholar
• •Important findings.
   Google Scholar
• GAUEN, GRIGIONI F, BACCHI-REGGIANI L et al.: Relation of endothelin-1 to survival in patients with primary hypertension. Eur. Clin. Invest. (1996) 26\(Suppl. 1):48.
   Google Scholar
• CHANNICK RN, RUBIN LJ, SIMONNEAU G et al:Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet (2001) 358:1119–1123.
   PubMed Web of Science ®Google Scholar
• ••Effects of ET antagonism in pulmonaryhypertension.
   Google Scholar
• ACTELION LTD: Oral endothelin receptor antagonist Tracleer meets primary endpoint in pulmonary arterial hypertension study. Press Release (2001) May 2.
   Google Scholar
• BARST RJ, RICH S, HORN EV et aL: Efficacy and safety of chronic treatment with the oral selective endothelin-A receptor blocker sitaxsentan in pulmonary arterial hypertension. Circulation (2000) 102:11-427, Abs 2076.
   Google Scholar
• TEXAS BIOTECHNOLOGY CORP: ICOS Corporation and Texas Biotechnology Corporation initiate a pivotal trial in pulmonary arterial hypertension. Press Release ( 2001) May 30.
   Google Scholar
• RICH S, KAUFMANN E, LEVY PS: Theeffect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl. I Med. (1992) 327:76–81.
   PubMed Web of Science ®Google Scholar
• FUSTER V, STEELE PM, EDWARDS WD, GERSH BJ, MCGOON MD, FRYE RL: Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation (1984) 70:580–587.
   PubMed Web of Science ®Google Scholar
• BARST RJ, RUBIN LJ, MCGOON MD, CALDWELL EJ, LONG WA, LEVY PS: Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann. Intern. Med. (1994) 121:409–415.
   PubMed Web of Science ®Google Scholar
• ROUX S, BREU V, ERTEL SI, CLOZEL M: Endothelin antagonism with bosentan: a review of potential applications. J. MoL Med. (1999) 77:364–376.
   PubMed Web of Science ®Google Scholar